Literature DB >> 1684559

Immunohistochemical detection of the multidrug transport protein P170 in human normal tissues and malignant lymphomas.

S A Pileri1, E Sabattini, B Falini, P L Tazzari, F Gherlinzoni, M G Michieli, D Damiani, L Zucchini, M Gobbi, T Tsuruo.   

Abstract

Two monoclonal antibodies, MRK16 and C219, both directed at the 170 kDa P-glycoprotein multidrug resistance agent, were applied to frozen sections or cytospin preparations from normal human tissues and 60 non-Hodgkin's malignant lymphomas. Adrenal gland, kidney, liver and pancreas were always stained by the reagents, albeit with slightly different patterns. Brain capillaries as well as macrophages and some elements of the bone marrow, peripheral blood, ovarian stroma and colonic, gastric and jejunal mucosa were positive in all examined preparations. There were differences in the staining patterns with the two antibodies. Among the 60 non-Hodgkin's lymphomas, 25 contained a number of positive cells, which ranged from 2% to 100%. No correlation was seen between the expression of P170 and histological type, stage, clinical symptoms or growth fraction. A close relationship was shown between the presence of P170 positive elements and the clinical course of the disease (P less than 0.001).

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1684559     DOI: 10.1111/j.1365-2559.1991.tb00003.x

Source DB:  PubMed          Journal:  Histopathology        ISSN: 0309-0167            Impact factor:   5.087


  13 in total

1.  Biology and modulation of multidrug resistance (MDR) in hematological malignancies.

Authors:  Masao Hirose
Journal:  Int J Hematol       Date:  2002-08       Impact factor: 2.490

2.  Detection of P-glycoprotein on endothelial and endocrine cells of the human pancreatic islets by C 494 monoclonal antibody.

Authors:  D Bani; M L Brandi; C A Axiotis; T Bani-Sacchi
Journal:  Histochemistry       Date:  1992-11

3.  A new mdr-1 encoded P-170 specific monoclonal antibody: (6/1C) on paraffin wax embedded tissue without pretreatment of sections.

Authors:  E Moran; A Larkin; G Doherty; P Kelehan; S Kennedy; M Clynes
Journal:  J Clin Pathol       Date:  1997-06       Impact factor: 3.411

Review 4.  Multidrug resistance (MDR) genes in haematological malignancies.

Authors:  K Nooter; P Sonneveld
Journal:  Cytotechnology       Date:  1993       Impact factor: 2.058

5.  Detection of the multidrug resistance marker P-glycoprotein by immunohistochemistry in malignant lung tumours.

Authors:  T W Beer; D C Rowlands; J Crocker
Journal:  Thorax       Date:  1996-05       Impact factor: 9.139

6.  New immunohistochemical "sandwich" staining method for mdr1 P-glycoprotein detection with JSB-1 monoclonal antibody in formalin-fixed, paraffin-embedded human tissues.

Authors:  K Tóth; M M Vaughan; H K Slocum; M A Arredondo; H Takita; R M Baker; Y M Rustum
Journal:  Am J Pathol       Date:  1994-02       Impact factor: 4.307

7.  Relationship between P-glycoprotein expression and cyclosporin A in kidney. An immunohistological and cell culture study.

Authors:  R García del Moral; F O'Valle; M Andújar; M Aguilar; M A Lucena; J López-Hidalgo; C Ramírez; M T Medina-Cano; D Aguilar; M Gómez-Morales
Journal:  Am J Pathol       Date:  1995-02       Impact factor: 4.307

Review 8.  P-glycoprotein-mediated multidrug resistance in normal and neoplastic hematopoietic cells.

Authors:  T Licht; I Pastan; M Gottesman; F Herrmann
Journal:  Ann Hematol       Date:  1994-10       Impact factor: 3.673

9.  Functional expression of the P-glycoprotein mdr in primary cultures of bovine cerebral capillary endothelial cells.

Authors:  D Lechardeur; D Scherman
Journal:  Cell Biol Toxicol       Date:  1995-10       Impact factor: 6.691

Review 10.  Antiretroviral therapy : pharmacokinetic considerations in patients with renal or hepatic impairment.

Authors:  Sarah M McCabe; Qing Ma; Judianne C Slish; Linda M Catanzaro; Neha Sheth; Robert DiCenzo; Gene D Morse
Journal:  Clin Pharmacokinet       Date:  2008       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.